Preclinical molecular imaging using PET and MRI.

Area of Science:

• Oncology
• Medical Imaging
• Translational Research

Background:

• Cancer research is transitioning from morphological assessments to in vivo functional and molecular characterization.
• Preclinical molecular imaging utilizes advanced methodologies and probes in animal models to study human cancers.
• Developing non-invasive techniques is crucial for characterizing neoplastic tissue and monitoring anti-cancer therapies.

Purpose of the Study:

• To review the principles, capabilities, and limitations of molecular imaging techniques in preclinical cancer research.
• To highlight the potential of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) for clinical translation.
• To discuss the use of animal models as surrogates for human cancers in molecular imaging studies.

Main Methods:

• Focus on Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) as primary molecular imaging modalities.
• Review of interdisciplinary developments in imaging methodology and probe molecules.
• Utilizing animal models of human cancers for preclinical investigations.

Main Results:

• PET and MRI offer complementary capabilities for molecular imaging with high potential for clinical translation.
• These techniques enable non-invasive assessment of key cancer hallmarks including hypoxia, angiogenesis, apoptosis, gene expression, metabolism, and cell trafficking.
• The study outlines prerequisites and consequences of using animal models in preclinical cancer imaging.

Conclusions:

• Molecular imaging, particularly PET and MRI, revolutionizes cancer research by providing in vivo molecular insights.
• Preclinical molecular imaging facilitates a deeper understanding of cancer biology and treatment response.
• These advanced imaging modalities hold significant promise for improving cancer diagnosis and therapy.